Vaccine Development
Moderna starts human trials of an mRNA-based flu shot
Moderna gave its mRNA-based seasonal flu vaccine to the first set of volunteers in a clinical trial, the pharmaceutical company announced today. The start of the trial marks the next stage of the company’s work on this type of vaccine technology after the overwhelming success of its COVID-19 vaccine, which was built using the same strategy. Before the COVID-19 pandemic, mRNA vaccines were still largely experimental, even as they were heralded as the future of vaccine development. People who get an mRNA vaccine are injected with tiny snippets of genetic material from the target virus. Their cells use that genetic information to build bits of the virus, which the body’s immune system learns to fight against. The high efficacy of the mRNA COVID-19 vaccines made by Moderna and Pfizer / BioNTec...
ECOWAS suggests compensation for coronavirus vaccine adverse reactions
The Economic Community of West African States (ECOWAS) Vaccine Taskforce has recommended compensation for citizens who suffer side effects or injury from the COVID-19 vaccination. Professor Stanley Okolo, the Director-General of the West African Health Organisation (WAHO), disclosed this at the 5th Regional Steering Committee meeting of the Regional Disease Surveillance Systems Enhancement (REDISSE) project on Saturday in Abuja. Okolo said that the recommendation was one of the resolutions adopted by the taskforce and presented to the ECOWAS Ministerial Coordinating Committee to encourage citizens to receive the vaccine. He explained during the REDISSE virtual meeting that the issue of indemnity was being taken up by the COVID-19 Vaccines Global Access, the global initiative aimed at equit...
